Mr. Brady has been Tempest’s chief executive officer since June 2021, first joining the company in September 2019 as president and chief operating officer. Most recently, he served as executive vice president, strategy and finance at Immune Design, a biopharmaceutical company sold to Merck in 2019. At Immune Design, Mr. Brady led strategy, corporate development, finance and investor and public relations, as well as other general and administrative functions, and was instrumental in the company’s successful IPO, financings and eventual sale. Prior to Immune Design, he held roles of increasing responsibility in multiple biopharmaceutical companies, including as vice president of corporate development at Proteolix, where he had primary responsibility for the company’s business development activities and sale to Onyx Pharmaceuticals. Mr. Brady also serves on the Board of Directors and Audit Committee of Atreca, Inc. and Board of Directors of the Biotechnology Innovation Organization (BIO).
CEO, Tempest Therapeutics
Join our email list to receive exclusive offers